Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experience

Basit Öğe Kaydı
dc.contributor.authorSoyer, Nur
dc.contributor.authorPatir, Pusem
dc.contributor.authorUysal, Ayse
dc.contributor.authorDuran, Mustafa
dc.contributor.authorUnal, Hatice Demet
dc.contributor.authorDurusoy, Raika
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorSahin, Fahri
dc.contributor.authorTobu, Mahmut
dc.contributor.authorVural, Filiz
dc.contributor.authorSaydam, Güray
dc.date.accessioned2019-10-27T10:45:21Z
dc.date.available2019-10-27T10:45:21Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients' records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment was one (1-4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32 and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent prognostic factors for OS and PPS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due to AEs. Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.en_US
dc.description.sponsorshipCelgene Corporationen_US
dc.description.sponsorshipEditorial assistance in the preparation of this manuscript was provided by Sandralee Lewis, PhD, of the Investigator Initiated Research Writing Group (an initiative of Ashfield Healthcare Communications, a part of UDG Healthcare plc), and was funded by Celgene Corporation.en_US
dc.identifier.doi10.3906/sag-1712-160en_US
dc.identifier.endpage785en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid30119153en_US
dc.identifier.startpage777en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1712-160
dc.identifier.urihttps://hdl.handle.net/11454/31134
dc.identifier.volume48en_US
dc.identifier.wosWOS:000441766000012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLenalidomideen_US
dc.subjectdexamethasoneen_US
dc.subjectmultiple myelomaen_US
dc.subjectefficacyen_US
dc.subjectsafetyen_US
dc.titleEfficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu